Will Rosen is the co-managing partner of the firm's London office and a partner in the private equity transactions group in London, his practice focuses on private equity and mergers & acquisitions.
Will has a broad range of experience in the corporate and corporate finance fields. His experience covers a wide range of corporate transactions, and he is recognised in particular for his work in advising private equity funds and corporate clients on mergers and acquisitions and private equity transactions. Will is recognised in The Legal 500, Chambers & Partners and The Guide to the World's Leading Private Equity Lawyers directories as a recommended practitioner in private equity. He is known for his “very collegial style” and for his ability to “read commercial situations and relay them to the client.” He has a high level of experience in private equity work and is known for handling a series of big-ticket deals.
- Acting for Bain Capital in connection with its:
- purchase of a controlling stake in MKM, the UK's largest independent builders' merchant, from 3i and Lloyds Development Capital.
- acquisition of NGA UK, a UK payroll and HR Business from NGA Human Resources.
- acquisition of the Ibstock, Forticrete, Supreme and Glen Gery clay and concrete businesses of CRH plc.
- acquisition of TI Automotive.
- Acting for Baring Private Equity Asia in connection with its:
- joint acquisition with PAI Partners of World Freight Company International, the global leader in the General Sales and Service Agent market.
- US$1.8 billion sale, alongside the Shanghai-based Bright Food Group, of British breakfast cereal brand Weetabix to U.S.-based cereal company, Post Holdings.
- Represented Marquee Brands LLC in its acquisition of British men's clothing brand Ben Sherman and its related intellectual property assets from Oxford Industries, Inc.
- Acting for Kanders & Company and its portfolio company The Safariland Group, on the acquisition of the Med-Eng explosive ordinance disposal and crew survivability businesses from the Allen-Vanguard Corporation.
- Acting for Summit Partners in connection with its:
- disposal of the entire issued share capital of Actix International Limited to Amdocs Limited.
- joint venture with FleetCor to acquire UK-based Masternaut from Francisco Partners.
- Acting for Wright Medical Technology, Inc. on its US$3.3 billion merger with Tornier N.V.
- Acting for Smedvig Capital in connection with its
- sale of Ocean Outdoor to Lloyds Development Capital and acting for management in the subsequent sales to Searchlight Capital.
- sale of Tuskerdirect Limited to ECI Partners LLP.
- Acting for Oxford Immunotec Global plc on its listing on the NASDAQ Global Market.
- Acting for a PERE Fund on the sale of Executive Offices Group for £260 million to Queensgate Investments.